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Preclinical studies have demonstrated the synergistic anti-tumour activity of combination therapy with the oral cytostatics, 50-deoxy-
5-fluorouridine (50-DFUR) and cyclophosphamide (CPA), in human breast cancer xenograft models. This study was performed to
evaluate the efficacy and safety of this oral combination chemotherapy in the treatment of metastatic breast cancer. In all, 101
patients with metastatic breast cancer were enrolled in the study, and the data for 94 eligible patients of these were evaluated. The
patients received twice daily oral combinations of 50-DFUR (1200mg/body/day) and CPA (100mg/body/day) for 2 weeks, followed
by a 1-week rest period. After a median of 19 treatment cycles (range 1–66 cycles), 16 patients (17.0%) had a complete response,
and 40 patients (42.6%) had partial responses. The response rate was 59.6% (95% CI, 49.0–69.6%). The median time to progression
and overall survival times were 11.7 and 40.3 months, respectively. The toxicity was mild and tolerable, and the related grade 3/4
clinical adverse effects consisted of haematological toxicity in 21 patients (22%) and nonhaematological toxicity in five patients (5%).
These results suggest that the oral combination chemotherapy of 50-DFUR and CPA has low toxicity and is a novel, very convenient
and effective treatment for metastatic breast cancer.
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Metastatic breast cancer is generally considered to be incurable
and conventional cytotoxic chemotherapy is used mainly for
palliation (Henderson et al, 1989). Standard chemotherapeutic
regimens for metastatic breast cancer utilise drugs such as
anthracyclines that are widely used and taxanes, (Greenberg et al,
1996; Burris, 1999; Nabholtz et al, 1999). Although standard
combination chemotherapy with anthracyclines and taxanes
results in significant response rates in first-line usage, the duration
of this response is short lived and the percentage of patients in
whom this treatment results in a cure is extremely low, even when
a complete response is obtained (Greenberg et al, 1996; Nabholtz
et al, 1999). When the standard regimens fail, there are a few other
effective chemotherapeutic regimens. The advent of novel
therapeutic regimens with reduced toxicity is therefore highly
desirable.
50-deoxy-5-fluorouridine (50-DFUR, doxifluridine), an inter-
mediate metabolite of capecitabine (Xeloda
s), is an orally
administered prodrug of fluorouracil (Cook et al, 1979; Ishitsuka
et al, 1980; Miwa et al, 1998; Ishitsuka, 2000), which exerts its
anticancer activity after metabolic conversion to 5-flourouracil (5-
FU) by pyrimidine nucleoside phosphorylase (PyNPase, thymidine
phosphorylase: TP in humans) (Kono et al, 1983), a strong
angiogenic factor identical to platelet-derived endothelial cell
growth factor (PD-ECGF) (Furukawa et al, 1992). There are higher
levels of this enzyme in the neoplastic tissue than in the normal
tissue (Nishida et al, 1996; Takebayashi et al, 1996), and 50-DFUR
therefore exhibits selective activity against various neoplasms
while having relatively low systemic toxicity (Niitani et al, 1985;
Uehara et al, 1985; Ishikawa et al, 1995). The response rate with 50-
DFUR monotherapy for the treatment of metastatic breast cancer
has been reported to be 35.9% (Niitani et al, 1985).
Sawada and Endo et al discovered that particular cytostatics,
such as taxanes, mitomycin C (MMC) and cyclophosphamide
(CPA), up-regulated TP expression preferentially in the tumour
tissue when therapeutic dose levels of these drugs were adminis-
tered, even after oral CPA administration, whereas TP was not
affected in normal tissues including the small intestine and liver.
Also, they demonstrated that combinations of 50-DFUR/capecita-
bine and these cytostatics exhibited excellent synergistic activity
against various human cancers in xenograft models, without
significant potentiation of toxicity (Sawada et al, 1998; Endo et al,
1999). Such synergistic activities were not recognised in combina-
tion with 5-FU nor UFT (a mixture of tegaful and uracil) and these
cytostatics (Endo et al, 1999). Of these cytostatics, we were
particularly interested in the combination of 50-DFUR and CPA as
both of these drugs can be administered orally (Yoshimoto et al,
1998).
A combination chemotherapy of 50-DFUR and CPA has been
reported to be more effective in preventing tumor recurrence than
50-DFUR alone in an adjuvant setting (Tominaga et al, 2003), but Revised 27 August 2003; accepted 2 September 2003
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lthe definitive evidence of the efficacy of this combination for
metastatic breast cancer has yet to be published. Based on these
previously reported preclinical and clinical results, we devised a
study wherein a combination of the two drugs was orally
administered to patients with metastatic breast cancer.
PATIENTS AND METHODS
Inclusion and exclusion criteria
Patients with the following criteria were included: patients with
bidimensionally measurable or assessable metastatic breast cancer
including inoperable stage IV breast cancer that had been
histologically, cytologically, or radiologically confirmed; patients
who had undergone treatment with a maximum of one previous
chemotherapy regimen for metastatic disease; patients with
progressive osseous metastases were eligible, but patients with
only osseous metastasis who had received radiotherapy were
excluded from the study. There were no age restrictions for this
study.
Patients with the following criteria were excluded: World Health
Organization (WHO) performance status greater than three, except
for cases of osseous metastasis; brain or leptomeningeal metas-
tases; serious cardiac, liver, kidney, or central nervous system
disease that precluded the treatment; a white blood cell count less
than 3000cellsml
 1, haemoglobin less than 9.0gdl
 1 or a platelet
count less than 100000cellsml
 1.
Patients were required to have passed a minimum of 4 weeks
after administration of their most recent chemotherapy, hormone
therapy, or radiation therapy, and to have recovered from all
treatment-related toxicity. Where possible, a histological or
cytological confirmation of diagnosis was performed.
Dose setting
The optimal maximum dosage for 50-DFUR monotherapy was
approved as 1200mg/body/day by Japan’s Ministry of Health and
Welfare at 1987, but sufficient rest periods (1 or 2 weeks) at
intervals of every 2 weeks of administration were also recom-
mended to prevent diarrhoea, a possible serious side effect of 50-
DFUR. Based on the initial dose setting, Ota et al found that a
combination therapy of 50-DFUR at doses of 1200mg/body/day
with CPA at 100mg/body/day for 2 weeks with a 2-weeks rest
period was safe and tolerable in a preliminary early Phase II trial
(Ohta et al, 1992). Tominaga et al developed a Phase III trial
comparing 50-DFUR plus CPA with 50-DFUR alone with the same
dose setting with or without tamoxifen in an adjuvant setting, and
revealed that the regimen was feasible and safe enough, causing
only 4.1% of grade Z3 side effects (Tominaga et al, 2003).
Experimental xenograft models, however, showed that 2-weeks rest
period was too long, whereas a 1-week rest period was adequate,
because the elevation of TP levels in the tumour tissue by CPA was
maintained over 1 week or less (Endo et al, 1999). In this study,
then, we adopted a dose setting as a daily oral combinations of 50-
DFUR (1200mg/body) and CPA (100mg/body) for 2 weeks,
followed by a 1-week rest period.
Treatment plan
This open-label Phase II trial, approved by the hospital’s
institutional review board (IRB), was performed in a single
institute and was designed to evaluate the safety and efficacy of
orally administered combination chemotherapy of 50-DFUR and
CPA.
All patients were fully informed of the potential benefits and
potential side effects of the proposed treatment, and gave written
informed consent to participate in the study prior to the start of
the study. If side effects were tolerable, the treatment was
continued until progression of the disease was recognised. No
other cytostatic agents or bisphosphonates were used during the
course of the treatment.
Patients were instructed to immediately stop taking the
medication if any kind of unusual diarrhoea or appetite loss
occurred. In such cases, treatment was resumed with a decreased
50-DFUR dosage of 800 or 600mg/body/day, without changing the
CPA dosage, after a sufficiently long rest period, usually 2 weeks. If
the resumed treatment with the decreased dose of 50-DFUR
induced the same side effects, the treatment was discontinued. For
patients in whom the absolute white blood cell count dropped to
2000ml
 1 or less, the rest period was extended by 1 week to a total
of 2 weeks.
Patients received treatment until disease progression or a
maximum of 3 years in the case of continuing complete response
to avoid the deterioration of bone marrow function and/or the
possibility of other serious side effects. Where possible, hormonal
maintenance treatments were allowed after this period.
Proper treatments after the progression of disease was not
determined in the study, but anthracycline-containing regimens
and/or taxanes were the usual treatment options administered
after progression of the disease if these drugs had not been
previously used.
Examination
Prior to the start of treatment, patients had their complete medical
history documented and had a physical examination, including the
measurement of tumour lesions, complete blood cell count, serum
chemistry, serum tumour markers (CEA and CA15-3), chest X-ray,
computed tomography or ultrasound examination of the liver,
ECG, and bone scintigraphy if clinically indicated. During the
study, on the first day of every treatment cycle, physical
examinations were performed and vital signs, complete blood cell
counts, serum chemistries and serum tumour markers were
determined. Tumour assessments using X-ray, CT scan, or
ultrasonography were performed every 6 weeks during the first 6
months and every 12 weeks after that period if the tumour was
considered to be stable. If at any time there was a significant
increase in the levels of serum tumour markers, a precise
assessment of the state of the tumour was performed. Tumour
assessments were also performed at the time of withdrawal from
the study.
Evaluation of response
Patients were considered assessable for response if they were
enrolled with accuracy, underwent the treatment under the
protocol, and had the first cycle of the treatment. The primary
efficacy end point was overall objective tumour response
(complete response (CR) and partial response (PR)), assessed
using the International Union Against Cancer (UICC) criteria
(Monfardini et al, 1987). The response for each patient was verified
by independent blinded peer review by radiologists. This peer
review assigned an assessment of overall tumour response: CR, PR
and stabilisation of the disease (no change, NC), progressive
disease (PD), or not assessable. Complete response, PR and NC
had to be confirmed on two occasions at least 4 weeks apart
(generally, at the next 6-week assessment).
A CR was defined as the total disappearance of clinically and
radiologically detectable disease for patients with measurable
disease, but was not defined for patients with unmeasurable lesions
such as osseous lesions. A PR was defined as at least a 50%
decrease in the sum of the product of the maximum perpendicular
diameters for all existing lesions, with no new lesions appearing.
Osteolytic bone lesions were regarded as assessable, and a PR in
osseous lesions required a partial decrease in the size of lytic
lesions and definite osteoblastic changes in osteolytic lesions to be
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less than 50% or an increase of less than 25% in the sum of the
product of the maximum perpendicular diameters of all existing
lesions, with no new lesions appearing. Among NCs, patients for
whom the cancer remained stable for over 6 months were defined
as long NC. A PD was defined if any new lesion appeared or if any
existing lesion increased by 25% or more. A PD for bone
metastasis was defined when increased in size of extent lesions
or the appearance of new lesions. Response rates were retro-
spectively evaluated with respect to menopausal status, receptor
status of the primary tumour, disease-free intervals, main sites of
metastasis for evaluation, prior exposure to cytostatics, and the
number of prior chemotherapy regimens for metastatic breast
cancer.
The other end points included time to progression (TTP) of
disease, and overall survival (OS) for the whole enrolled patients.
The duration was calculated using the standard WHO criteria.
Time to progression was determined as the interval between the
day on which treatment was initiated and the earliest day that the
progression was recognised, or the day of death from any cause.
The time to response was determined for patients who obtained
CR or PR as the interval between the day on which treatment was
initiated and the earliest day that a response was recognised. The
duration of the response was determined as the interval between
the day that the response was recognised and the earliest day that
disease progression was recognised, or the day of death from any
cause.
Evaluation of toxicity
Toxicity was evaluated for eligible patients according to the May
1998 revision of the National Cancer Institute (NCI) common
toxicity criteria grading system.
Statistical analysis
Time to progression and OS were estimated by the Kaplan–Meier
product–limit method. The overall objective tumour response
rates (CRs and PRs/whole) and clinical benefit rates (CRs, PRs and
long NCs/whole) were analysed by logistic regression, presenting
odds ratio with 95% confidence intervals (CI). P-values in w
2 tests
of less than 0.05 were considered statistically significant.
RESULTS
Patient and tumour characteristics
From June 1995 to December 2000, 101 patients with metastatic
breast cancer were enrolled and treated; of these 94 patients were
deemed to be eligible for analysis. The remaining seven patients
were judged as not eligible and were not included in the analysis
for the following reasons: three patients with osseous metastasis
were judged to have unevaluable lesions, four patients received
other concomitant therapy (hormonal therapy, or radiation
therapy, or administration of bisphosphonate agents for bone
metastases).
The patient characteristics for the eligible patients are listed in
Table 1. The main sites of metastasis for evaluation were the local
skin and/or the chest wall in 16 patients (including three patients
with lung metastasis and two patients with bone metastasis),
lymph node in 16 patients (including one patient with lung
metastasis, and one patient with bone metastasis), bone in 24
patients, lung in 21 patients, liver in 16 patients and massive
pleural metastasis in one patient. In all, 68 patients (72%) had one
or more visceral sites of metastasis, and 23 patients (24%) had two
or more sites of metastasis. A total of 62 patients (66%) had prior
exposure to both 5-FU and CPA in the form of CMF (CPA,
methotrexate and 5-FU) or CAF (CPA, doxorubicin and 5-FU), and
12 patients (13%) had prior exposure to anthracyclines.
Efficacy
After a median of 19 treatment cycles (range 1–66 cycles), there
were 16 (17.0%) CRs, 40 (42.6%) PRs, and 20 (21.3%) NCs
(Table 2). Among NCs, the disease status of 13 patients remained
stable for longer than 6 months (long NC). The overall response
rate (CRþPR/whole) was 59.6% (95% CI, 49.0–69.6%). The
response rate for first-line chemotherapy for metastatic disease in
68 patients was 64.7% (95% CI, 52.2–75.9%), including 14 CRs
Table 1 Patient characteristics
Characteristics No. %
Age (years)
%40 7 7
41–50 22 23
51–60 36 38
61–70 21 22
Z71 8 9
Mean (range) 55.5 (31–77)
Menopausal status
Pre- 20 21
Post- 74 79
Receptor status
ER-positive 44 47
-negative 24 26
-unknown 26 28
PgR-positive 37 39
-negative 29 31
-unknown 28 30
Performance status
07 5 8 0
11 2 1 3
24 4
^33 3
Disease-free interval
%23 6 3 8
2–5 years 36 38
45 years 22 23
No. of metastatic organs
16 7 7 1
22 4 2 6
Z33 3
Main sites of metastasis
Skin/chest wall 16 17
Lymph nodes 16 17
Bone 24 26
Lung 21 22
Liver 16 17
Pleura (massive) 1 1
Prior exposure to cytostatics
Hormonal only 14 15
Chemo only 34 36
Chemo+hormonal 34 36
None 12 13
No. of prior chemotherapy regimens for MBC
06 8 7 2
12 6 2 8
ER¼oestrogen receptor; PgR¼progesterone receptor; MBC¼metastatic breast
cancer.
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l(20.6%). The response rate for 26 patients as a second-line
chemotherapy was 46.2%. The overall clinical benefit rate
(CRþPRþlong NC/whole) was 73.4% (95% CI, 63.3–82.0 %).
Among the enrolled whole 101 patients, 82 patients had
progressive disease at the end of December 2001. Of the remaining
19 patients who had not progressed, nine remained as CRs and six
remained as PRs. In all, 48 patients had died and 53 patients were
alive. All, but one patient, who had CRs are alive after a median
follow-up time of 36.8 months. The median (50%) TTP was 11.7
months, and 1- and 3-year TTPs were 49 and 23%, respectively
(Figure 1). The median OS was 40.3 months, and 1-, 3- and 5-year
overall survival rates were 86, 57 and 24%, respectively (Figure 2).
The median TTP and OS for patients, in whom the treatment was
used as first-line chemotherapy, were 12.7 and 45.6 months,
respectively. For responders, the median time to response was
4.070.4 months (range 0.7–15.0 months). The median response
duration was 17.471.8 months (range 1–52þ months).
Tumour responses with regard to clinical status are shown in
Table 2. In all, 11 (68.8%) of 16 patients with liver metastasis
responded to the treatment, including four patients who had a CR
for 9–32 months. For the 62 patients with prior exposure to 5-FU
and CPA in the form of CMF or CAF, a 59.7% response rate was
obtained. The response rates for patients with oestrogen and/or
progesterone receptor positive were as high as 72.7 and 81.0%,
respectively, although all the hormone-receptor positive patients
were hormone refractory. Also, there were significant differences
in the response rate with regard to the receptor status of the
primary tumour. In total, 12 patients with prior exposure to
anthracyclines had a 50% response rate.
Toxicity
The oral combination chemotherapy was well tolerated by most
patients. The main toxic side effects are shown in Table 3.
Haematological toxicity was observed, but was generally mild
and progressed slowly; only 21 (22%) patients had developed grade
3 toxicity. Grade 4 haematological toxicity was not observed in any
patient. Diarrhoea and/or appetite loss were the most serious side
effects, however, these side effects were observed in four patients,
of whom two were successfully managed with a reduction of the 50-
DFUR dosage to 800 or 600mg/body/day, without changing the
CPA dosage after a sufficiently long period of rest. Grade 4
pulmonary toxicity occurred in one patient who developed
interstitial pneumonia and died. This patient had previously
undergone long-term treatment with CPA in the form of CMF for
2.5 years. Hand-foot syndrome, a common toxic side effect of
capecitabine, was not observed. Significant liver or renal function
toxicity was not observed, and cardiac insufficiency or alopecia
were not observed.
Granulocyte colony-stimulating factor (G-CSF) nor special
antiemetic drugs (such as antiserotonin agents) were not necessary
to use during the course of treatment.
DISCUSSION
Our results show that the oral combination chemotherapy of 50-
DFUR and CPA was not only convenient, but also effective in the
treatment of metastatic breast cancer with mild side effects. The
overall response rate of 59.6% (64.7% for first-line usage), the CR
rate of 17.0% and the median TTP of 11.7 months match the values
obtained by standard polychemotherapy regimens with anthracy-
clines (Rahman et al, 1999), previously reported as 65.0%, 16.6%
and 11.5 months, respectively. The median survival time of 40.3
months is, however, significantly longer than the 21.3 months they
reported.
It is thought that these results are partly due to the presence of
some synergistic activity in the combination therapy of 50-DFUR
and CPA, because a high response rate of 59.7% was obtained in
patients who had prior exposure to both 5-FU and CPA in the form
of CMF or CAF. It may also be due to the fact that both 50-DFUR
and CPA are less toxic and less immunosuppressive than standard
polychemotherapy regimens (Ohta et al, 1980; Tanaka et al, 1990).
In addition, both the drugs can be administered for long periods of
time (longer than 2 or 3 years) with mild side effects, as both drugs
have different dose-limiting toxicities, digestive toxicity with 50-
DFUR and haematological toxicity with CPA. The two drugs also
exhibit different kinds of anticancer activities, with 50-DFUR
having activity against CPA-resistant cancer cells (Endo et al,
1997). This combination therapy may have a non-cross-resistant
anti-cancer activity with anthracyclines (Table 2) and/or with
taxanes (data not shown). A combination of these factors may help
to explain the high response rate and significantly longer median
survival times observed in this study.
We have demonstrated that this treatment is effective, and that
oral therapy offers many advantages over the standard infusion
chemotherapy. The convenience of oral chemotherapy increases
the treatment options for many patients with metastatic breast
cancer. The reduction in side effects and the lack of severe nausea
and vomiting, general fatigue, cardiac insufficiency and alopecia,
which are usually caused by the standard infusion chemotherapy,
helps patients to maintain their quality of life. An additional
advantage of this therapy is that it should reduce the costs
associated with the treatment of metastatic breast cancer, as it does
not require hospital admission, rescue treatments such as G-CSF,
or antiserotonin agents. In addition, mild and slow decreases in the
bone marrow function allow for relatively longer intervals between
monitoring examinations.
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Figure 1 Time to progression (TTP) curves for whole patients.
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Figure 2 Overall survival curve for whole patients after the beginning of
the treatment.
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lExperimental researches with regard to TP upregulation,
preferentially in tumour tissue by taxanes, MMC and CPA (Sawada
et al, 1998; Endo et al, 1999), propose the possible potentiality of
the combination therapy of these cytostatics and 50-DFUR or
capecitabine. 50-DFUR and CPA therapy by Yoshimoto et al
(1998), and capecitabine and taxotere (TXT) therapy by O’Shaugh-
nessy et al (2002), for breast cancer showed successful clinical
examples. Although other ideal dose settings or combination
therapies using 50-DFUR/capecitabine and cytostatics that exert TP
up-regulation may exist, the problem remains to be seen in the
optimal timing of administration of drugs in order to achieve
maximum clinical effectiveness, since the process of TP up-
regulation in tumour tissue by particular cytostatics takes a
number of (4–6) days and TP levels gradually decrease after the
discontinuation of treatment in the human cancer xenograft
models (Sawada et al, 1998; Endo et al, 1999). There remain many
other unresolved questions raised in this study. For example, why
hormone refractory, receptor-positive breast cancers exhibited
significantly higher sensitivity to the treatment, or why such a long
median overall survival rate was obtained? These also need to be
investigated. Further research is necessary.
In conclusion, the oral combination chemotherapy of 50-DFUR
and CPA exhibits low toxicity, and is a very convenient and
effective treatment for metastatic breast cancer. This chemother-
apy regimen may present a new treatment option for patients with
metastatic breast cancer. Future clinical studies should compare
this treatment with the existing standard treatment regimens for
metastatic breast cancer.
Table 2 Tumour responses with regard to clinical status
Response
Clinical status No. of patients CR PR NC (long NC) PD Response rate (%) (CR+PR/whole) 95% Confidence interval Significance
Whole eligible patients 94 16 40 20 (13) 18 59.6 49.0–69.6 —
Menopausal status
Pre- 20 6 7 2 (0) 5 65.0 40.1–84.6 NS
Post- 74 10 33 18 (13) 13 58.1 46.1–69.5
Receptor status
ER-positive 44 9 23 7 (4) 5 72.7 54.8–83.2 } Po0.05
-negative 24 2 8 6 (5) 8 41.7 22.1–63.4
-unknown 26 5 9 7 (4) 5 53.8 33.4–73.4
PgR-positive 37 9 21 5 (3) 2 81.0 64.8–92.0 } Po0.05
-negative 30 2 9 8 (6) 11 37.9 19.9–56.1
-unknown 27 5 10 7 (4) 5 53.6 35.3–74.5
Disease-free interval
r2 years 36 5 13 8 (6) 10 50.0 32.9–67.1 NS
2–5 years 36 5 18 7 (3) 6 63.9 46.2–79.2
45 years 22 6 9 5 (4) 2 68.2 45.1–86.1
Main sites of metastasis
Skin/chest wall 16 4 3 7 (5) 2 43.8 19.8–70.1 NS
Lymph nodes 16 4 6 2 (1) 4 62.5 35.4–84.8
Bone 24 0 16 5 (3) 3 66.7 44.7–84.4
Lung 21 4 7 4 (3) 6 52.4 29.8–74.3
Liver 16 4 7 2 (1) 3 68.8 41.3–89.0
Pleura (massive) 1 0 1 0 0 100
Prior exposure to cytostatics
Hormonal only 14 0 8 4 (4) 2 57.1 28.9–82.3 NS
Chemotherapy only 34 7 12 7 (4) 8 55.9 37.9–72.8
Chemo+hormonal 34 8 13 8 (4) 5 61.8 43.6–77.8
None 12 1 7 1 (1) 3 66.7 34.9–90.1
No. of prior chemotherapy regimens for MBC
0 68 14 30 14 (9) 10 64.7 52.2–75.9 NS
1 26 2 10 6 (4) 8 46.2 26.6–66.6
CR¼complete response; PR¼partial response; NC¼no change; PD¼progressive disease; ER¼oestrogen receptor; PgR¼progesterone receptor; MBC¼metastatic breast
cancer.
Table 3 Toxicities
CTC Grade (NCI, May 1998)
Variable 1 2 3 4 % (Grade 3+4)
Haematological toxicity
Leucocytopenia 27 41 19 0 20.2
Granulocytopenia 21 39 16 0 17.0
Anaemia 14 18 3 0 3.2
Thrombocytopenia 25 5 0 0 0.0
Digestive toxicity
Diarrhoea 6 2 4 0 4.3
Appetite loss 14 6 4 0 4.3
Nausea 12 3 3 — 3.2
Pulmonary toxicity 0 0 0 1 1.1
Liver and renal toxicity 21 0 0 0 0.0
Alopecia 0 0 — — —
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